Acta Pharmaceutica Sinica B
|
2026, 16(6): 3985-3987
• Commentaries •
Potential oncogenic risks of Keap1-targeting PROTACs: Caution warranted in drug design
Full
Zhe Zhao1,2, Wen Ma3, Jincen Hao4, Gaofei Hu4, Xinfeng Wang5,6
Affiliations
1 Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China;
2 Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China;
3 School of Basic Medicine, Qingdao University, Qingdao, Shandong 266071, China;
4 The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Health Science Center, Peking University, Beijing 100191, China;
5 Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;
6 State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
doi: 10.1016/j.apsb.2026.03.040
Outline
Keap1
/
Nrf2
/
homoPROTAC
/
Redox homeostasis
/
Oncogenesis
Zhe Zhao, Wen Ma, Jincen Hao, Gaofei Hu, Xinfeng Wang.
Potential oncogenic risks of Keap1-targeting PROTACs: Caution warranted in drug design[J].
Acta Pharmaceutica Sinica B,
2026
, 16
(6)
: 3985
-3987
.
DOI: 10.1016/j.apsb.2026.03.040
Year 2026 volume 16 Issue 6
PDF
8
5
Cite this Article
BibTeX
Article Info
doi: 10.1016/j.apsb.2026.03.040
- Receive Date:2025-11-13
- Online Date:2026-09-17